This was followed by appearance of vesicles over the palms, elbows, and buttocks. The child subsequently developed bullae over both the soles, painful in nature, making the child irritable [ Figure 2a and b]. The child also refused to feed due to ongoing symptoms which made the parents extremely anxious. Oral acyclovir was given in a dose of 10 mg/kg/dose 4 times a day. By the 3 rd day, there was a significant improvement in the clinical status of the child. The child started to feed within 48 h of starting acyclovir. The bullae and vesicles almost dried up within 72 h [ Figure 2c ]. However, acyclovir was continued for a total duration of 7 days.
Case 3
A 2-year-old male child presented with extensive distribution of vesicles over the buttocks and lower limbs progressing to erosions and ulcerations. The child had typical oval-shaped vesicles on an erythematous base over the palms and soles. Oral examination revealed discrete erosions over the palate. The clinical condition of the patient deteriorated rapidly, worsened by the decreased food intake and accompanying high-grade fever. He was admitted under the care of a pediatrician for supportive treatment. In view of classical clinical features suggestive of HFMD, the child was started on oral acyclovir in a dose of 10 mg/kg/dose 4 times a day. This was continued for 7 days with a good response.
discussion
HFMD is a relatively mild childhood viral disease caused by coxsackievirus A16 (CVA16) or HEV71 but may occasionally be caused by CVA 4-7, A9, A10, B1-3, and B5. This condition is known to occur as periodic outbreaks, with predilection for summer and early fall in temperate climates, but throughout the year in the tropics. [6] Although maximum number of cases occur in children under the age of 10 years, adult cases have also been reported in literature. [8] Usually, HFMD has self-resolving course, although there are a few exceptional cases which have an extremely aggressive clinical presentation and need to be treated on a priority. Mathes et al. identified four morphologies that characterize the severe end of the spectrum of HFMD and distinguish it from classic HFMD: (1) widespread vesiculobullous and erosive lesions extending beyond the palms and soles, (2) an eczema herpeticum-like eruption termed "eczema coxsackium," (3) an eruption similar to Gianotti-Crosti, and (4) a petechial or purpuric eruption. [9] Currently, there is no specific effective antiviral available to tackle HFMD cases. Acyclovir, the most widely used antiviral drug, exerts its therapeutic effect by undergoing phosphorylation to be activated into acyclovir triphosphate. [10, 11] This action is done first by thymidine kinase (present in viruses such as herpes simplex, herpes zoster, and Epstein-Barr virus) and consequently by cellular enzymes. The triphosphylated form of acyclovir inhibits viral DNA, resulting in irreversible inhibition of further viral DNA synthesis. Enteroviruses, however, lack thymidine kinase, and in vitro studies have failed to show any inhibitory effect of acyclovir on them. [12, 13] Thus, acyclovir is believed to work in HFMD by modulating the patient's own interferon for its antiviral effect. [14] Shelley et al. [12] demonstrated the valuable therapeutic effect of acyclovir in 12 children and one adult with HFMD in 1996. These patients were treated with oral acyclovir (200-300 mg five times daily for 5 days) within 1-2 days of onset of the rash. Symptomatic relief, defervescence, and significant involution of lesions were seen within 24 h of starting acyclovir.
Other situations where it may be reasonable to consider treatment with oral acyclovir include in infants who generally have a more severe course and in severely symptomatic patients. Rarely, myocarditis, meningitis, encephalitis, paralysis, or pulmonary edema can occur. [15, 16] These serious complications and even death are much more likely to be associated with epidemics of HEV71 rather than CVA16 and may warrant oral acyclovir. Infection with coxsackie A16 has been associated, however, with fatal rhabdomyolysis and renal failure, [17] and with spontaneous abortion in the first trimester of pregnancy. [18] In a resource-poor setting with no laboratory support to confirm the diagnosis, it would be worthwhile to consider acyclovir in the management of clinically diagnosed severe HFMD cases. However, multicenter, randomized, controlled studies for severe cases of HFMD are required for validating the role of acyclovir.
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